---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-270377"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2023-11-03T23:59:59+00:00"
generated_at: "2026-06-08T22:42:39.041685+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sensei Biotherapeutics reports favorable Phase 1/2 data for SNS-101 at SITC 2023

## Summary
- SNS-101 dose escalation (13 patients): well-tolerated, no DLTs, no CRS; only one related AE (Grade 2 dermatitis).
- Pharmacokinetics: dose-proportional exposure, linear elimination, no target-mediated drug disposition; supports every-three-week dosing.
- SNS-101 achieved dose levels >10x higher than a competitor VISTA antibody that was halted due to CRS, suggesting best-in-class potential.
- Expected data readouts: initial combo safety/PK data Q1 2024, topline monotherapy Q2 2024, topline combo later in 2024.
- Late-breaking poster at SITC 2023 on Nov 4; data supports conditionally active VISTA-blocking approach.

## SEC filing metadata
- accession: 0001193125-23-270377
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2023-11-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312523270377/0001193125-23-270377-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312523270377/d556062d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-270377
- JSON: https://secwatch.observer/filing/0001193125-23-270377.json
- Plain text: https://secwatch.observer/filing/0001193125-23-270377.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.